NCT06607107View on ClinicalTrials.gov

mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 17, 2024

Primary Completion Date

January 11, 2026

Study Completion Date

January 11, 2028

Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
DRUG

mFOLFOX7 combined with Camrelizumab and apatinib

mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER